A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2013
At a glance
- Drugs Ixabepilone (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 02 Feb 2010 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 29 May 2008 Status changed from in progress to completed, as reported on clinicaltrials.gov
- 01 May 2008 Results published in Annals of Oncology.